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Abstract 
Our previous study reported that stemofoline (STF) exhibited a synergistic effect with chemotherapeutic 
drugs in human multidrug-resistant (MDR) leukemic cells (K526/Adr) by inhibiting the function of P-
glycoprotein, which is a membrane transporter that is overexpressed in several types of MDR cancers. 
This study further investigated the effects of a combination treatment of STF and doxorubicin (DOX) in 
vitro and in vivo. The combination treatment of 50 mg/kg of STF strongly enhanced the anti-tumor activity 
of DOX in SCID-beige mice bearing K562/Adr xenografts without additional toxicity when compared to the 
single treatment groups. Additionally, an examination of the proliferation markers (Ki67) and the apoptotic 
marker (TUNEL) in tumor tissues in each group revealed that the combination therapy significantly 
reduced Ki67 positive cells and increased apoptotic cells. From the in vitro experiments we also found 
that this combination treatment dramatically induced G1 and G2M arrest in K562/Adr when compared to 
a single treatment of DOX. STF treatment alone did not show any cytotoxic effect to the cells. These 
results suggest that the accumulation of DOX enhanced by STF was sufficient to induce cell cycle arrest 
in K562/Adr. These findings support our previous in vitro data and indicate the possibility of developing 
STF as an adjuvant therapy in cancer treatments. 
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Introduction
Leukemia is a cancer that affects the blood and 
bone marrow, the spongy center of bones where 
blood cells are formed. Leukemia treatment usually 
involves chemotherapy, bone morrow implantation and 
radiotherapy (Baruchel et al., 2009; Matsumura, 2009). 
Chronic myeloid leukemia (CML) is a myeloproliferative 
disorder of hemopoitic stem cells. The incident rate 
of CML in males has been reported to be higher than 
the rate for females (male/female ratio is 1.3-1.5:1) 
(Quintas-Cardama and Cortes, 2006; Mendizabal et al., 
2013). There has been some improvement in survival 
rates since the introduction of therapeutic drugs including 
the anthracyclines (doxorubicin, epirubicin), the vinca 
alkaloids (vinblastine, vincristine) and methotrexate, 
L-asparaginase and alkylating agents (Norgaard et al., 
2004). Chemotherapy for CML treatment uses one or 
usually at least two of the above-mentioned chemical 
substances. Such treatments not only destroy or reduce 
tumor cell growth but also increase the 5-year survival rates 
for cancer patient. However, resistance to anti-neoplastic 
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drugs can develop in several types of cancer patients 
who have taken chemotherapy over long periods of time 
(Tiwari et al., 2011; Binkhathlan and Lavasanifar, 2013). 
Chemo-resistance or multidrug resistance (MDR) 
is a major problem in cancer treatments. The various 
mechanisms of MDR include overexpression of drug 
transporters, an increase in detoxification mechanisms 
along with an induction of DNA repairing enzymes, 
and altered drug targets (deletion, translocation and 
amplification of drug target) (Gottesman et al., 2002; Fojo 
and Menefee, 2007; Lage, 2008). The causes of death in 
leukemic patients are infection, loss of muscle control and 
heart failure. However, several studies have described the 
increased P-gp expression after the initial chemotherapy 
treatment that has repeatedly been linked to poor outcomes 
in some forms of leukemia (Marie et al., 1996; Leonard 
et al., 2003). Doxorubicin (DOX) is an effective form of 
chemotherapy against both hematological malignancy and 
solid tumors. DOX exhibited higher efficacy on leukemic 
patient by reduction of blast cells in blood circulation. 
Anti-tumor mechanisms of DOX are achieved by the 
induction of free radicals, which are linked to DNA 
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damage, and inhibition of DNA and RNA synthesis by 
inhibition of topoisomerase II (Rabbani et al., 2005; 
Rogalska et al., 2008; Szwed et al., 2016). However, 
DOX has been shown to give rise to the development 
of drug resistance, which might be due to an increase in 
P-glycoprotein (P-gp) expression (de Moraes et al., 2013). 
Many P-gp inhibitors have been reported, such 
as the first generation drugs verapamil, quinidine 
and cyclosporine A, and the second generation drugs 
dexverapamil, emopamil and PSC833. Therefore, 
researchers have tried to identify the third-generation of 
P-gp inhibitors (with prolonged half-life and reduction 
of toxicity) from plants or natural products. These agents 
are currently being studied in clinical trials (Krishna and 
Mayer, 2000; Leonard et al., 2003). We have focused on 
natural compounds as inhibitors of P-gp to enhance the 
efficacy of anticancer drugs against MDR cancer cells. 
Many natural product P-gp inhibitors have been reported, 
including curcumin (Anuchapreeda et al., 2006; Limtrakul 
et al., 2007), kuguacin J (Pitchakarn et al., 2012) and 
calidonine (El-Readi et al., 2013). 
Stemona plants that are found in East and South-east 
Asia are important herbal plants with various medicinal 
and pharmacological properties. Plant extracts obtained 
from Stemona tubulosa, S. sessilifolia and S. japonica 
have been reported for their antitrussive activities in 
mouse model studies (Hu et al., 2009). The S. tubulosa 
extract has been reported to have an anti-inflammatory 
effect of the lungs in cigarette smoke-induced pulmonary 
inflammation both in vitro and in vivo (Lee et al., 2014; 
Lim et al., 2015). The S. tubulosa and S.collinsae extracts 
have been reported to have anti-proliferative effects on the 
medullary thyroid carcinoma cell line (Li et al., 2007). 
However, the activity of Stemona plant extracts against 
drug resistant cancer cells has not yet been reported. In our 
previous studies we reported that the extract of Stemona 
burkillii could enhance the chemotherapeutic sensitivity 
in human MDR cervical carcinoma (KB-V1) cells 
(Chanmahasathien et al., 2011a; Pyne SG et al., 2017). We 
then purified and identified the active compound identified 
as the Stemona alkaloid stemofoline (STF).
In our previous studies we found that STF showed 
significant synergistic effects with conventional anti-
cancer agents against KB-V1 and human MDR leukemic 
cells (K526/Adr). STF inhibited P-gp function leading to 
increases of P-gp fluorescent substrates (calcein-AM and 
rhodamine 123) and [14C]-DOX intracellular accumulation 
in KB-V1 and K562/Adr cells (Chanmahasathien et al., 
2011a; Umsumarng et al., 2013; Umsumarng et al., 
2015). The biochemical mechanism of STF could be that 
it reverses the MDR cancer phenotype by inhibition of 
P-gp function via direct interaction with the substrate 
binding domain but by without affecting P-gp expression 
(Chanmahasathien et al., 2011b). However, the MDR 
reversal property of STF in an animal model has not yet 
been demonstrated. In this study, we further investigated 
the effect of the combination treatment of STF and DOX 
in an animal model. We first investigated the acute toxicity 
of STF by acute toxicity testing and studied the MDR 
modulating property of STF in MDR leukemic cells in 
a xenograft model. Next, we determined the mechanism 
for synergistic effect of STF and DOX in MDR leukemic 
cells in vitro.
Materials and Methods
Stemofoline extraction and isolation
STF was isolated from Stemona burkillii root extract 
and its structure is shown in Figure 1. Dried root powders 
were extracted with a solution of 95% of ethanol three 
times at room temperature. The ethanolic extract was 
combined and evaporated using a rotary evaporator. STF 
was purified as previously described (Sastraruji et al., 
2010; Chanmahasathien et al., 2011a; Sastraruji et al., 
2012).
Cells and cell culture
K562/Adr (human MDR leukemic cell line, CML) 
was purchased from RIKEN Cell Bank (Tsukuba, 
Ibaraki, Japan). K562 (human drug sensitive leukemic 
cell line) was purchased from The American type Culture 
Collection (ATCC, Manassas, VA, U.S.A.). Both cell 
lines were maintained and cultured in a 37°C humidified 
atmosphere comprised of 5% CO2 in RPMI-1640 (Nissui 
Pharmaceutical Co., Ltd., Taito-ku, Tokyo, Japan) with 
10% fetal bovine serum (FBS), 5 mm L-glutamine, 50 
IU/mL penicillin and 50 g/ mL streptomycin. When the 
cells reached 70–80% confluence, they were harvested 
and plated either for subsequent passages or for drug 
treatments. K562/Adr cells were routinely maintained 
in RPMI-1640 culture medium containing 700 nM of 
doxorubicin (DOX, Sigma Chemical Co., St. Louis, MO, 
U.S.A.) and grown in a drug-free medium for at least two 
days before the experiment.
Animals
All animal experiments were performed under 
protocols approved by the Committee of Animal Care 
and Use of Saitama University. Eight-week-old male 
ICR mice and 6-week-old male SCID-Beige mice were 
purchased from Charles River Japan, Inc. (Atsugi, Japan) 
and housed in plastic cages with bedding consisting of 
hardwood chips in an air-conditioned room at 23±2oC and 
at 55±5% humidity with a 12 h light/dark cycle. Diet and 
autoclaved water were available ad libitum.
Acute toxicity testing
The acute toxicity of STF was evaluated using 
eight-week-old 5 male ICR mice. The ICR mice were 
intraperitoneally (i.p.) injected with STF (50 mg/kg BW) 
according to OECD 420 guidelines. Mice morbidity and 
mortality were recorded daily. After treatment for two 
weeks, the surviving mice were sacrificed and LD50 values 
were calculated. Mice serum samples were collected 
to investigate liver function by determining alanine 
aminotransferase (ALT) and aspartate aminotransferase 
(AST) levels. Renal function was tested by determination 
of blood urea nitrogen (BUN) and creatinine levels. 
Internal organs (liver, spleen, heart, lungs and kidneys) 
were measured and gross examination was observed on 
abnormal lesions. Consequently, sections of the internal 
organs were fixed in 10% of formaldehyde in PBS. These 
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Chemo-sensitivity testing by MTT colorimetric assay
Cell viability of each leukemic cell line was measured 
using the MTT assay. Drug sensitive human leukemic 
cells (K562) and human MDR leukemic cells (K562/Adr) 
were plated in a 96-well-plate at a concentration 2.0×103 
cells/well. After 24h, the cells were treated with 0-40 µM 
of DOX with or without 5 µM of STF. Cell lines were 
incubated under a temperature of 37oC at 5% of CO2. 
After 48 hours of treatment, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT, Sigma Chemical 
Co., St. Louis, MO, U.S.A.) was added to each well for 
4h. RPMI-1640 medium was then removed and 200 μL of 
DMSO (Wako Pure Chemical Ind., Ltd., Chuo-ku, Osaka, 
Japan) was added to the specimen. Each leukemic cell line 
was incubated at 37oC, 5% CO2 for 4 h. Cell viability was 
assessed by determining the mean of MTT colorimetric 
assay.  In each experiment, determinations were carried 
out in triplicate. IC50 value of each cell line was calculated.
Apoptosis analysis by annexin V and propidium iodine 
(PI) staining
K562/Adr cells were plated in a 6-well plate at a 
concentration of 5.0×105 cells/well. After 24h, the cells 
were treated with various concentrations of DOX (0-5 
µM) in the absence or presence of 5 µM of STF for 48 h. 
Cells were then collected and washed twice with ice-cold 
PBS. The cell line was stained with annexin V-FITC and 
PI according to the manufacturer’s instructions using the 
annexin V-FITC apoptosis detection kit (BioVision Inc., 
Milpitas, CA, U.S.A.). Apoptotic cells were detected 
by flow cytometry. Annexin V-positive cells were 
considered indicative of early apoptosis. Both annexin V 
and PI-positive cells were considered indicative of late 
apoptosis.
Cell cycle analysis by propidium iodine (PI) staining
K562/Adr cells were plated in a 6-well-plate at a 
concentration of 5.0×105 cells/well. After 24hrs, the cells 
were treated with various concentrations of DOX (0-5 µM) 
with or without 5 µM of STF for 48 hours. Leukemic cells 
were collected and washed twice with ice-cold PBS. The 
cell line was fixed with 70% cold ethanol for 30 minutes 
and incubated for 30 minutes by 0.25 mg/mL of RNase 
A in 1.12% of sodium citrate buffer.  Finally, the cell 
line was stained with PI for 30 minutes. Cell cycling was 
performed by flow cytometry.
Statistical analysis
All in vitro experiments were performed in at least 
triplicate to confirm reproducibility. Statistical analyses 
were performed with mean ±S.D. values using one-way 
ANOVA, the Bonferroni correction and Dunnett’s test. 
Statistical significance was determined at p < 0.05, 
p< 0.01 or p< 0.001.
Results
Acute toxicity study of STF
The acute toxicity study of STF was evaluated using 
five eight-week-old male ICR mice. The ICR mice were 
i.p. injected with highest solubility of STF (50 mg/kg 
sections of internal organs were prepared for paraffin 
embedding. The paraffin sections were then stained 
by H and E. Pathological evaluation was conducted 
by a Veterinarian Pathologist. The acute toxicity was 
determined by mice body weight, mice survival rate, 
gross examination and histopathological examination 
of internal organs and the data were compared with the 
references values.
Effect of STF on DOX sensitivity in a K562/Adr xenograft 
model 
Human multidrug resistant leukemic cell (K562/
Adr) xenograft model was used for an investigation of 
the MDR reversing property of STF on DOX sensitivity. 
Six-week-old male SCID-beige mice (20 mice) were 
implanted with K652/Adr cells (5.0 x 106 cells) 
subcutaneously at the flank area of the mice (Beider 
et al., 2014). The tumors on the flank area of the mice 
were palpated every day. As soon as the tumors reached 
100-200 mm3 in volume, the mice were divided into 4 
groups: 1) vehicle control; 0.9% NaCl; IP 2) STF 50 mg/
kg BW; IP, 3) DOX 2 mg/kg BW; IV and 4) DOX 2 mg/
kg BW; IV plus STF 50 mg/kg BW; IP, respectively. For 
the combination treatment group, 50 mg/kg BW of STF 
was administered for 30 minutes before DOX was applied. 
These treatments were applied every 4 days for 16 days. 
The mice that bore tumors were measured every 3 days 
and their weights were measured every 4 days. After 
which, all mice were sacrificed and primary tumors were 
removed and measured in terms of weight and volume 
(formula; axis 1 x axis 2 x axis 3) x 0.52 (Pitchakarn 
et al., 2012; Punfa et al., 2014). Internal organs (liver, 
spleen, heart, lungs and kidneys) were inspected for 
abnormal lesions. Sections of the primary tumors and 
internal organs were then fixed in 10% of formaldehyde 
in PBS. These sections of the internal organs were used 
to prepare paraffin embeds. Paraffin sections were stained 
with H and E. Pathological evaluations were conducted by 
Veterinarian Pathologist. Tumor sections were processed 
for H and E, Ki67 immunohistochemistry staining and 
terminal deoxynucleotidyl transferase mediated dUTP 
nick end labeling (TUNEL) assay.
Immunohistochemistry
For Ki67 immunostaining, paraffin-embedded 
specimens were sectioned (5 µm) and stained with Ki67 
antibody (clone SP6) (Acris Antibodies GmbH, Herford, 
Germany) and then with anti-rabbit secondary antibody 
and avidin–biotin complex (Vectastatin Elite ABC kit; 
Vector Laboratory, Burlingame, CA). After which, the 
binding sites were visualized with diamino-benzidine. 
The sections were then counterstained lightly with 
hematoxylin for microscopic examination.
TUNEL assay
Apoptotic index values were determined by TUNEL 
assay. The assay was performed using ApopTag® 
Peroxidase In Situ Apoptosis Detection Kit (Merck 
millipore Billerica, Massachusetts, USA).
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BW) for 2 weeks. Our result shown that all mice were not 
observed acute toxicity. There were no differences in the 
body weight and internal organ weight when compared 
to the reference materials (Table 1).
STF-enhanced sensitivity of MDR leukemic cells to 
chemotherapeutic drug in vivo
Our results found that co-administration of DOX+STF 
reduced the tumor volume of K562/Adr cells implanted 
in the back area of SCID-Beige mice when compared 
administration with the control (p=0.3827), with STF 
(p=0.1371) and with DOX (p=0.4091) (Figure 2A and B). 
Moreover, tumor weight also significant reduced when 
the mice was co-administration with DOX+STF when 
compare with control, STF and DOX (Figure 2C). An 
adverse effect on the body weight (Figure 2D) and internal 
organs (Table 2) of the host SCID-Beige mice was not 
detected. In addition, there is no histological lesion was 
observed in H and E staining of liver, spleen, heart, lung 
and kidney of all the treatment mice (Figure 2E). 
H and E, Ki67 and TUNEL staining are shown 
in Figure 3A. The Ki67 labeling index value was 
significantly reduced in the combination treatment group 
(Figure 3B) and TUNEL-positive cells of the transplanted 
tumor tissues were shown to have significantly increased 
in the combination treatment group (Figure 3C). These 
results could suggest that the treatment of STF and DOX 
revealed a significant synergistic effect by reducing 
cell proliferation and inducing apoptosis in K562/Adr 
transplantation SCID-beige mice.
STF-enhanced sensitivity of MDR leukemic cells to 
chemotherapeutic drug
We examined the MDR reversing property of STF and 
DOX co-administration in K562/Adr (MDR leukemic 
cells) and K562 (drug sensitive cells) cell lines. We found 
that co-administration of STF and DOX significantly 
induced growth inhibition in a dose dependent manner 
when compared with DOX single treatment in K562/
Adr (p<0.001). This modulating effect was not found 
with a similar administration of DOX and STF to K562 
cells (Figure 4A and B). Moreover, we demonstrated that 
treatment K562 and K562/ADR with STF 50 µM for 48h 
were not show cytotoxic to K562 and K562/Adr cells 
Parameters Mouse#1 Mouse#2 Mouse#3 Mouse#4 Mouse#5 Mean±SD Ref.
Mice BW (g) (start) 33.5 31.88 32.4 34.1 33.8 33.14±0.95 30.50±2.60a
Mice BW (g) (end) 31.62 32.62 32.51 33.06 33.1 32.58±0.60 32.50±3.40a
Survival rate (%) 100 100 100 100 100 100.00±0.00 -
Liver (g) 2 1.84 1.95 2.01 2.05 1.97±0.08 1.878±0.248a
Spleen (g) 0.14 0.13 0.13 0.14 0.16 0.14±0.01 0.145±0.021a
Heart (g) 0.22 0.23 0.23 0.24 0.24 0.23±0.01 0.175±0.023a
Rt. Kidney (g) 0.4 0.37 0.43 0.39 0.44 0.41±0.03 0.441±0.062a
Lt. Kidney (g) 0.4 0.31 0.41 0.35 0.4 0.37±0.04
ALT (U/L) 15 15 20 13 14 15.40±2.70 37.0±9.10b
AST (U/L) 124 90 60 94 83 90.20±23.03 100.00±14.60b
BUN (mg/dL) 26 27 26 30 28 27.40±1.67 28.54±3.16b
Creatinine (mg/dL) 0.3 0.3 0.3 0.3 0.3 0.30±0.00 0.43±0.18b
Table 1. Effect of STF on Acute Toxicity in Animal Models
ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; BUN, Blood urea nitrogen; aCharles River Laboratories Tech. 1986; bLaurie el 
al., 2003. 
Parameters Vehicle control group STF treated group DOX treated group DOX+STF treated group
Mice BW (g) (start) 24.10±1.35 24.03±1.16 25.97±1.06 24.23±1.58
Mice BW (g) (end) 22.20±1.84 22.73±2.32 21.87±1.62 20.83±1.97
Survival rate (%) 100 100 100 100
Liver (g) 1.03±0.15 1.22±0.16 1.08 ±0.27 1.07±0.12
Spleen (g) 0.04±0.02 0.05±0.01 0.03±0.01 0.02±0.01
Heart (g) 0.13±0.02 0.13±0.02 0.15±0.05 0.10±0.03
Rt. Kidney (g) 0.24±0.02 0.23±0.05 0.20±0.02 0.17±0.03
Lt. Kidney (g) 0.18±0.04 0.23±0.07 0.19±0.02 0.19±0.02
Tumors weight (g) 1.7±0.03 2.05±0.67 2.03±0.09 0.99±0.17
Table 2. Effect of Treatment on the Body Weight and Internal Organs of Host SCID-Beige Mice
Figure 1. Structure of STF
Asian Pacific Journal of Cancer Prevention, Vol 19 3537
DOI:10.31557/APJCP.2018.19.12.3533
Stemofoline and Doxorubicin Synergistic Effect Against Human Multidrug Resistant Leukemic Cells 
Figure 2. Potentiation of Antitumor Effects of DOX by STF in K562/Adr Xenograft Model. Mice were treated with 
saline (control); STF alone at 50 mg/kg; DOX alone at 2 mg/kg; doxorubicin at 2 mg/kg plus STF 50 mg/kg (STF was 
given 30 minutes before DOX administration). Tumor volumes were monitored during the experiment by a Vernier 
caliper (D0-D16) (A). After scarification (day 16) time, tumors were removed for measure tumor volume (B) and 
tumor weight (C). Changes in body weight during the experiment were recorded (D). Microphotographs of H&E 
sections of internal organs from SCID-Beige mice after treatment with saline (control); STF alone at 50 mg/kg; DOX 
alone at 2 mg/kg; doxorubicin at 2 mg/kg plus STF 50 mg/kg (STF was given 30 minutes before DOX administration). 
Mice were sacrificed for pathologic examination 4 day after the last administration. Original magnification (x20) (E)
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Figure 3. Tumor Masses were Cross-Sectioned and Fixed in 10% Formalin Buffer and Prepared in Paraffin Embed 
Block. They were then stained with H and E and immunohistochemistry (A); (Ki67) proliferation marker and apoptotic 
marker (TUNEL). % of proliferation marker (Ki67)-positive cells (B) and % of apoptotic marker (TUNEL)-positive 
cells (C) were analyzed using Image J software.
Figure 4. MDR Modulation Effect of STF on DOX Sensitivity in K562/Adr (A) and K562 Cell Lines (B) was 
determined. The co-administration of DOX (0-40 µM) with or without STF was performed by MTT colorimetric 
assay for 48 hrs. The mean value from three independent experiments is shown and error bars indicating SD (n = 3) 
are shown as ***p <0.001 versus DOX single administration at each indicated concentration.
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(Figure 4C). The results suggested that STF could enhance 
the sensitivity of the MDR leukemic cell line to DOX.
Enhanced sensitivity of MDR leukemic cells to 
chemotherapeutic drug by apoptosis and cell cycle arrest 
induction 
Next, we investigated the effect of the STF and DOX 
co-administration induced program of cell death in K562/
Adr cells. The results indicated that co-administration of 
DOX and STF slightly revealed apoptosis induction in 
K562/Adr cells when compared to a single administration 
on both early and late apoptosis (Figure 5A-C). Next, 
cell-cycle determination in MDR leukemic cells was 
performed to confirm that the growth inhibition was due 
to the action of DOX. It was found that co-administration 
treatment of DOX and STF significantly induced G2/M 
phase arrest in K562/Adr cells at co-administration of 
DOX 1 µM (p <0.05) and 5 µM (p <0.001) when compared 
to the single administration (Figure 6A-C). The results 
suggested that the co-administration treatment of DOX 
and STF induced G1 and G2/M phase arrest.
Figure 5. STF Enhanced Sensitivity of K562/Adr Cells to DOX. The graphs represent living cells (A), early apoptosis 
(B) and late apoptosis cell populations (C). K562/Adr cells were treated with various concentrations of DOX (0-5 µM) 
with or without 5 µM of STF for 48 hrs. After treatment, K562/Adr were washed twice with PBS and stained with 
annexin V and propidium iodide (PI). Apoptosis induction was determined by flow cytometry. The mean values from 
three independent experiments are shown and error bars indicate SD (n = 3). 
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Discussion
P-gp is a member of the transport protein superfamily 
called ATP-binding cassette (ABCB1/P-gp). It is a 
170-kDa transmembrane glycoprotein, which plays a 
major role in multidrug resistance (MDR) in various forms 
of cancer, such as in human cervical carcinoma cells, breast 
cancer adenocarcinoma cells and human leukemic cells 
(Acharyya et al., 2012). Moreover, it has a wide-spectrum 
substrate capacity, including for several chemotherapeutic 
drugs (anthracyclin, vinca alkaloids and paclitaxel) and 
fluorescence dyes (Calcein-AM and rhodamine 123). 
Therefore, P-gp can be the target for cancer treatment in 
order to enhance the efficacy of chemotherapeutic drugs 
in MDR cancer patients. Chemo-sensitizers or P-gp 
modulators are agents that abrogate the drug accumulation 
defect present in P-gp-expressing cancer cells. The 
magnitude of the chemo-sensitizer effects could be 
determined by comparing the IC50 values for a cytotoxic 
drug in the absence and presence of a relatively non-
Figure 6. STF Enhanced Sensitivity of K562/Adr Cells to DOX. The graphs represent G1 (A), S (B) and G2/M phase 
distribution (C). K562/Adr cells were treated with various concentrations of DOX (0-5 µM) with or without 5 µM of 
STF for 48 hrs. After treatment, K562/Adr cells were washed twice with PBS and stained with propidium iodide (PI). 
Cell cycle phase distribution was determined by flow cytometry. The mean value from three independent experiments 
is shown and error bars indicate SD (n = 3). *p <0.05, **p <0.01 and ***p <0.001 versus DOX single administration 
at each indicated concentration.
Asian Pacific Journal of Cancer Prevention, Vol 19 3541
DOI:10.31557/APJCP.2018.19.12.3533
Stemofoline and Doxorubicin Synergistic Effect Against Human Multidrug Resistant Leukemic Cells 
toxic, fixed concentration of the chemo-sensitizer 
(Marie et al., 1996). Verapamil (VER) and cyclosporine 
A (CSA) have been reported to be P-gp modulators in 
P-gp-mediated MDR cancer cells (Sharom et al., 1999; 
Krishna and Mayer, 2000), but they have limitations 
in clinical use due to their side effects (Ford and Hait, 
1990). This has generated the need to search for new 
effective MDR modulators that have been isolated from 
natural products and that do not produce adverse side 
effects. A previous study reported that Stemona curtisii 
root extract, which contains Stemona alkaloids (Greger, 
2006), modulated P-gp activity in human cervical cancer 
cells and the KB-V1 cell line (high P-gp expression). 
However, this was not the case with Multidrug resistant 
related protein-1 (MRP-1) activity in the MRP1-HEK293 
cell line (high MRP-1expression). The results obtained 
from the present study strongly supported the finding 
that the Stemona plant extract may show a promising 
role as a P-gp modulator. In 2011, the MDR reversing 
property of three Stemona alkaloids (stemocurtisine; STC 
oxystemokerrine; OST and stemofoline; STF) isolated 
from Stemona burkillii (Chanmahasathien et al., 2011a) 
were studied and it was found that STF had the most potent 
effect on enhancing cancer drug sensitivity against human 
MDR cervical carcinoma cells (Chanmahasathien et al., 
2011b). However, one limitation of natural compounds 
is that the variations of concentrations of the active 
compounds depend on the area of cultivation or the plant 
species. To solve this problem, semi-synthetic methods 
can increase the yields of active compounds and improve 
the compound efficacy by side chain modification of the 
parental core structure.
Stemona plants are comprised of three genus; Stemona, 
Croomia and Stichoneuron. The underground parts of the 
plant, roots and rhizomes have been used in Ayurvedic 
medicines with broad applications in Thailand, China and 
Japan. It has been reported that Stemona collinsiae root 
extract exhibited antineoplastic properties (Rungrojtrakool 
et al., 2012) and biological activity against human herpes 
virus (Akanitapichat et al., 2005). The investigation of 
the anti-cancer properties of Stemona alkaloids obtained 
from Stemonaceae holds significant promise for the 
development of more effective chemotherapeutic or 
adjuvant agents in cancer treatments. Previous studies 
point out the significant functional group that might 
regulate the P-gp modulating effect of Stemona alkaloids 
(Umsumarng et al., 2017). STF is a major alkaloid 
present in Stemona curtisii and Stemona burkillii, which 
is found in the southern and northern parts of Thailand, 
respectively (Kongkiatpaiboon et al., 2011). Additionally, 
DSTF is a major alkaloid of Stemona collinasae, which is 
found in the eastern part of Thailand (Kongkiatpaiboon 
et al., 2011). Recently, it has been reported that Stemona 
alkaloids isolated from Stemona curtisii could inhibit P-gp 
activity, whereas other alkaloids purified from Stemona 
javanica and Stichonueron halabalesis did not exhibit this 
property (Umsumarng et al., 2017). It could be concluded 
that alkaloid variations in the different Stemona species 
have an influence on their P-gp modulating activity. 
The present study supported the findings of previous 
studies that stated that the type of Stemona alkaloids 
included in Stemona plants can be used to indicate their 
chemosensitizing ability (Chanmahasathien et al., 2011a; 
Chanmahasathien et al., 2011b; Umsumarng et al., 2017). 
In the animal experiments, STF, a major alkaloid found 
in Stemona burkillii and Stemona curtisii that strongly 
exerts MDR reversal property, was selected to determine 
its chemosensitizing effect in vivo. Acute toxicity testing 
of STF in ICR mice was determined and it was found 
that all ICR mice could survive after i.p. injection of STF 
(50 mg/kg BW). Notably, there no lesions were found in 
the heart, lungs, liver, kidneys, or spleen as determined 
by gross and histopathology examinations. Furthermore, 
blood chemistry  analysis showed that ALT, AST, BUN 
and creatinine levels were normal suggesting that the 
function of the liver and kidneys in the STF-treated mice 
was not altered. The results indicate that 50 mg/kg BW 
of STF was found to be safe and can be utilized in further 
investigations. The P-gp modulating effect of STF was 
next evaluated in K562/Adr bearing SCID-beige mice. 
Twenty male SCID-beige mice were subcutaneously 
injected with K562/Adr cells in the flank area. The tumor 
size was measured every day. As soon as the tumor 
volume reached 100-200 mm3, the mice were divided 
into 4 groups: 1) vehicle control; 0.9% NaCl; I.P., 2) STF 
treatment (50 mg/kg BW; I.P.), 3) DOX treatment (2 mg/kg 
BW; IV) and 4) combination of DOX (2 mg/kg BW; IV) 
and STF (50 mg/kg BW; I.P.). After which, the treatment 
was initiated. Unfortunately, due to certain technical 
errors, tumor growth was observed in only in 12 of 20 
transplanted-mice. Consequently, tumors were identified 
in three mice in each group. The co-administration of 
DOX and STF was found to clearly reduce tumor size 
when compared with the vehicle control group (p=0.3827), 
STF (p=0.1371) and DOX (p=0.4091). The survival rate 
of SCID-Beige mice was 100%. The adverse effects on 
the body weight and internal organs of each group were 
not found to be different. Immunohistochemistry analyses 
found that the combined treatment significantly reduced 
the Ki67 proliferation marker (p<0.01) and induced 
apoptosis (TUNEL) (p<0.001) when compared to the 
DOX-treated group. Tumor growth did not differ in the 
single treatment of STF when compared to the control 
group. These results indicate that STF itself did not affect 
tumor growth, but STF was able to enhance the efficacy of 
DOX in K562/Adr-xenograft SCID-Beige mice. It can be 
concluded that STF could modulate P-gp-mediated MDR 
leading to an increased chemotherapeutic drug response 
in the animal model.
We have confirmed that STF and DOX co-administration 
induced program cell death by apoptosis analysis via flow 
cytometry. It was found that co-administration of DOX 
and STF initiated apoptosis induction in K562/Adr cells 
when compared to a single administration in both early 
and late apoptosis. The mechanism of DOX is a cell cycle 
non-specific agent. It could produce reactive oxygen 
species (ROS) and inhibit topoisomerase II leading to 
DNA damage and chromatin aggregation (Rabbani et al., 
2005). However, in treatments of 48 hours, STF could 
inhibit P-gp function leading to increasing intracellular 
DOX accumulation. The DNA damage response 
mechanism of the cancer cells may be halted in some 
Sonthaya Umsumarng et al
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cell-cycle phases by repairing the DNA. However, if 
cancer cells were unable to repair DNA, programed cell 
death could be induced by apoptosis signaling. 
Cell-cycle arrest in MDR leukemic cells was 
performed to confirm that the growth inhibition was due 
to the action of DOX by flow cytometry. It was found 
that the co-administration treatment of DOX and STF 
significantly induced G2/M phase arrest in K562/Adr cells 
through a co-administration of DOX 1 µM (p <0.05) and 5 
µM (p <0.001) when compared to a single administration. 
The results suggest that the co-administration treatment of 
DOX and STF induced G1 and G2/M phase arrest. Notably, 
DOX is the drug of choice to treat leukemic patients. DOX 
produces ROS and inhibits topoisomerase II leading to 
chromatin aggregation (Rabbani et al., 2005). It can arrest 
cancer cells in all cell-cycle phases and induces cell death. 
The results indicated that the DOX treatment caused cell 
accumulation at the G2/M phase, while the accumulation 
was shifted to sub-G1 and S populations when the cells 
were co-treated with STF. However, the cytotoxicity and 
growth inhibition might be due to the anti-cancer drugs 
that accumulated in the MDR cells and were stimulated by 
the STF. These results suggest that the compounds were 
able to enhance the drug sensitivity via the modulation 
of P-gp.
The present study provides scientific data on the 
biochemical mechanism of STF on P-gp overexpressing 
of MDR cancer cells. STF may be a candidate as a 
P-gp modulator as its toxicity is low and it produces no 
noticeable adverse effects. These compounds could be 
developed and used in combination with the conventional 
therapy of P-gp overexpressing in MDR cancer patients.
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